Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The U.S. Department of Defense awarded Osiris (NASDAQ:OSIR) a $224.7 million contract to develop and stockpile Prochymal for the repair of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury